She has been having hot flashes for six years. Her sleep has been broken for so long she has almost forgotten what a full night feels like. She stopped HRT before she ever started it because of something she read in a newspaper in 2002, a headline that said hormones cause breast cancer. She has been living with the consequences of that headline ever since, managing symptoms that have significantly affected her work, her relationships, and her sense of herself, because she believed a fear that was built on a misunderstanding. And she is not alone. There are millions of women like her.

The 2002 Women’s Health Initiative study, and the media coverage it generated, created a fear of hormone replacement therapy that altered the trajectory of menopause care for a generation. Twenty-plus years later, many women and many clinicians are still making decisions based on that fear rather than on the more nuanced, more complete picture that the research now offers.

This article will explain what the WHI study actually found and why it was misinterpreted, what the updated research says about HRT and breast cancer risk, how absolute risk differs from relative risk, and what the current consensus from major menopause societies looks like for women thinking about this decision.

What the 2002 WHI study actually showed

The Women’s Health Initiative was a large US government-funded study that looked at combined hormone therapy (estrogen plus progestin) in postmenopausal women. When the combined-arm of the study was stopped early in 2002, the headline finding was a statistically significant increase in breast cancer risk in women taking combined HRT.

What the media coverage did not communicate was the context. The women in the study had a mean age of 63. Many were more than ten years past menopause. They were not the population of women for whom HRT is most commonly indicated, which is women in perimenopause or early postmenopause. The formulation used was conjugated equine estrogen plus medroxyprogesterone acetate, which is not the same as modern body-identical (micronized) progesterone. And critically, the absolute risk increase was very small: the study found 8 additional breast cancer cases per 10,000 women per year in the HRT group compared to placebo.

That number matters. Eight additional cases per 10,000 women per year represents a relative risk increase of about 26%, which sounds alarming. But expressed as absolute risk, it is a very small difference, roughly comparable to the breast cancer risk associated with drinking one glass of wine daily, which most people do not consider an unacceptable risk.

The 2019 Lancet reanalysis and what it changed

A 2019 reanalysis published in The Lancet, often cited as the most comprehensive review of HRT and breast cancer data, pooled data from 58 studies involving nearly 109,000 women with breast cancer. It found that combined estrogen-progestogen HRT was associated with an increased breast cancer risk, and that this risk persisted for some years after stopping HRT.

This study has been widely cited as confirmation of the original WHI concern. But the picture it paints is more complex and more important than the headlines suggested. Several key nuances matter enormously for individual risk assessment.

The type of progestogen used matters significantly. Synthetic progestins like medroxyprogesterone acetate carry a higher breast cancer risk signal than body-identical micronized progesterone (Utrogestan). Multiple studies, including a large French cohort study published in the International Journal of Cancer, found that combined HRT using micronized progesterone was not associated with a statistically significant increase in breast cancer risk over five years of use, in sharp contrast to synthetic progestin formulations.

Estrogen-only HRT, taken by women who have had a hysterectomy, was actually associated with a reduction in breast cancer risk in the WHI study, and the 2019 Lancet reanalysis confirmed no meaningful increase in risk from estrogen-only therapy. This is a striking and consistently underreported finding.

Absolute versus relative risk: what you are actually weighing

Understanding the difference between relative risk and absolute risk is essential for making an informed decision about HRT.

If something doubles your risk of a rare event, that sounds frightening. But if your baseline risk was 1 in 1,000, doubling it takes you to 2 in 1,000. The relative risk has changed by 100%. The absolute risk has changed by 0.1 percentage points. These are very different ways of framing the same number.

For most women under 60 who start HRT within ten years of menopause, the absolute increase in breast cancer risk from combined HRT is small. The Menopause Society 2022 position statement notes that the risk for most women using modern HRT formulations, particularly those using body-identical progesterone, is lower than previously estimated and comparable to, or lower than, the risk associated with commonly accepted lifestyle factors such as alcohol consumption, obesity, and physical inactivity.

Dr. Kelly Casperson, whose work on The Menopause Moment podcast and in clinical practice has focused heavily on correcting HRT misinformation, notes that the absolute risk conversation is the one that patients deserve and rarely receive. The framing of HRT as simply “causing cancer” obscures a risk-benefit calculation that, for many women, comes out clearly in favor of treatment when properly explained.

What the Menopause Society’s current position says

The Menopause Society (formerly the North American Menopause Society) 2022 position statement on hormone therapy states clearly that for women under 60 or within ten years of menopause onset, the benefits of HRT outweigh the risks for most women with bothersome menopause symptoms. The statement notes that this recommendation applies to systemic HRT, not just low-dose vaginal formulations.

The statement also highlights that HRT has benefits beyond symptom relief, including protection of bone density, reduced cardiovascular risk when initiated at the right time, potential neuroprotective effects, and quality of life improvements, that are part of the full risk-benefit picture.

The timing of initiation matters. HRT initiated within ten years of menopause, or before age 60, has a different and more favorable profile than HRT initiated much later. This is one reason the WHI findings, based on a population whose average age was 63, have limited applicability to the typical candidate for menopause HRT.

How to have this conversation with your doctor

If you have been avoiding HRT because of the 2002 headlines, you are entitled to a fresh conversation with your doctor that uses current evidence rather than a misinterpreted twenty-year-old study.

Some specific things to ask about: the difference between synthetic progestin and body-identical micronized progesterone, whether estrogen-only HRT is appropriate if you have had a hysterectomy, your personal baseline breast cancer risk including family history and genetic factors, and how HRT fits into your complete health picture including bone, cardiovascular, and cognitive health.

If your doctor cannot engage with these questions or defaults to blanket refusals based on the 2002 study, seek a second opinion from a menopause-trained provider. The Menopause Society maintains a directory of certified menopause practitioners who have current knowledge of this evidence.

The fear was real. But for most women, it was built on an incomplete reading of the research. You deserve the full picture.

Medical disclaimer: This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or before starting any new treatment.